Alterations in estrogen signalling pathways upon acquisition of anthracycline resistance in breast tumor cells

por Chewchuk, Simon, Guo, Baoqing, Parissenti, Amadeo Mark
Publicado 2017

Bile Acids Increase Doxorubicin Sensitivity in ABCC1-expressing Tumour Cells

por Chewchuk, Simon, Boorman, Tyler, Edwardson, Derek, Parissenti, Amadeo M.
Publicado 2018

Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells

por Guo, Baoqing, Tam, Adam, Santi, Stacey A., Parissenti, Amadeo M.
Publicado 2016

Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization

por Heibein, Allan D, Guo, Baoqing, Sprowl, Jason A, MacLean, David A, Parissenti, Amadeo M
Publicado 2012

Inflammatory cytokine production in tumor cells upon chemotherapy drug exposure or upon selection for drug resistance

por Edwardson, Derek W., Boudreau, Justin, Mapletoft, Jonathan, Lanner, Carita, Kovala, A. Thomas, Parissenti, Amadeo M.
Publicado 2017

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells

por Wang, Harris, Vo, The, Hajar, Ali, Li, Sarah, Chen, Xinmei, Parissenti, Amadeo M, Brindley, David N, Wang, Zhixiang
Publicado 2014

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines

por Edwardson, Derek W., Narendrula, Rashmi, Chewchuk, Simon, Mispel-Beyer, Kyle, Mapletoft, Jonathan P.J., Parissenti, Amadeo M.
Publicado 2015

Role of drug transporters and drug accumulation in the temporal acquisition of drug resistance

por Hembruff, Stacey L, Laberge, Monique L, Villeneuve, David J, Guo, Baoqing, Veitch, Zachary, Cecchetto, Melanie, Parissenti, Amadeo M
Publicado 2008

Distinct genetic alterations occur in ovarian tumor cells selected for combined resistance to carboplatin and docetaxel

por Armstrong, Stephen R, Narendrula, Rashmi, Guo, Baoqing, Parissenti, Amadeo M, McCallum, Katherine L, Cull, Stephanie, Lannér, Carita
Publicado 2012

Sensitivity of docetaxel-resistant MCF-7 breast cancer cells to microtubule-destabilizing agents including vinca alkaloids and colchicine-site binding agents

por Wang, Richard C., Chen, Xinmei, Parissenti, Amadeo M., Joy, Anil A., Tuszynski, Jack, Brindley, David N., Wang, Zhixiang
Publicado 2017

Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response

por Zheng, Xiaobin, Andruska, Neal, Lambrecht, Michael J., He, Sisi, Parissenti, Amadeo, Hergenrother, Paul J., Nelson, Erik R., Shapiro, David J.
Publicado 2016

RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines

por Narendrula, Rashmi, Mispel-Beyer, Kyle, Guo, Baoqing, Parissenti, Amadeo M., Pritzker, Laura B., Pritzker, Ken, Masilamani, Twinkle, Wang, Xiaohui, Lannér, Carita
Publicado 2016

Alterations in tumor necrosis factor signaling pathways are associated with cytotoxicity and resistance to taxanes: a study in isogenic resistant tumor cells

por Sprowl, Jason A, Reed, Kerry, Armstrong, Stephen R, Lanner, Carita, Guo, Baoqing, Kalatskaya, Irina, Stein, Lincoln, Hembruff, Stacey L, Tam, Adam, Parissenti, Amadeo M
Publicado 2012

The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs

por Mapletoft, Jonathan P. J., St-Onge, Renée J., Guo, Baoqing, Butler, Phillipe, Masilamani, Twinkle J., D’costa, Lavina, Pritzker, Laura B., Parissenti, Amadeo M.
Publicado 2020

RNA disruption is a widespread phenomenon associated with stress-induced cell death in tumour cells

por Butler, Phillipe, Pascheto, Isabella, Lizzi, Michayla, St-Onge, Renée, Lanner, Carita, Guo, Baoqing, Masilamani, Twinkle, Pritzker, Laura B., Kovala, A. Thomas, Parissenti, Amadeo M.
Publicado 2023

RNA disruption indicates CHOP therapy efficacy in canine lymphoma

por Parissenti, Amadeo M., Pritzker, Laura B., Guo, Baoqing, Narendrula, Rashmi, Wang, Shirly Xiaohui, Lin, Lin Laura, Pei, Jingchun, Skowronski, Karolina, Bienzle, Dorothee, Woods, J. Paul, Pritzker, Kenneth P. H., Coomber, Brenda L.
Publicado 2019

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

por Trudeau, Maureen Elizabeth, Chapman, Judith-Anne W., Guo, Baoqing, Clemons, Mark J., Dent, Rebecca A., Jong, Roberta A., Kahn, Harriette J., Pritchard, Kathleen I., Han, Lei, O’Brien, Patti, Shepherd, Lois E., Parissenti, Amadeo M.
Publicado 2015